Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$123.34
2.031.67%
At close: -
$123.10
-0.24-0.19%
After Hours: 7:54 PM EDT
Comments
Loading...
TransMedics Group Analyst Ratings and Price Targets | NASDAQ:TMDX | Benzinga
TransMedics Group Inc has a consensus price target of $112.17 based on the ratings of 14 analysts. The high is $178 issued by Stephens & Co. on August 2, 2024. The low is $70 issued by JP Morgan on November 7, 2023. The 3 most-recent analyst ratings were released by Oppenheimer, Piper Sandler, and Piper Sandler on May 9, 2025, May 9, 2025, and April 29, 2025, respectively. With an average price target of $120 between Oppenheimer, Piper Sandler, and Piper Sandler, there's an implied -2.52% downside for TransMedics Group Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Piper Sandler
Canaccord Genuity
JP Morgan
Baird
1calculated from analyst ratings
Analyst Ratings for TransMedics Group
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2025 | Buy Now | 5.61% | Oppenheimer | Suraj Kalia59% | $125 → $130 | Maintains | Outperform | Get Alert |
| 05/09/2025 | Buy Now | 1.54% | Piper Sandler | Matt O'Brien53% | $105 → $125 | Reiterates | Overweight → Overweight | Get Alert |
| 04/29/2025 | Buy Now | -14.7% | Piper Sandler | Matt O'Brien53% | $90 → $105 | Reiterates | Overweight → Overweight | Get Alert |
| 04/23/2025 | Buy Now | — | Needham | Mike Matson57% | — | Reiterates | Hold → Hold | Get Alert |
| 03/26/2025 | Buy Now | — | Needham | Mike Matson57% | — | Reiterates | Hold → Hold | Get Alert |
| 03/11/2025 | Buy Now | -15.52% | Canaccord Genuity | William Plovanic60% | $104 → $104 | Maintains | Buy | Get Alert |
| 02/05/2025 | Buy Now | — | Needham | Mike Matson57% | — | Reiterates | Hold → Hold | Get Alert |
| 12/17/2024 | Buy Now | -39.07% | JP Morgan | Allen Gong46% | $116 → $75 | Downgrade | Overweight → Neutral | Get Alert |
| 12/11/2024 | Buy Now | -26.89% | Piper Sandler | Matt O'Brien53% | $110 → $90 | Maintains | Overweight | Get Alert |
| 12/11/2024 | Buy Now | -2.52% | Baird | Joe Vruwink75% | $150 → $120 | Maintains | Outperform | Get Alert |
| 12/11/2024 | Buy Now | — | Needham | Mike Matson57% | — | Reiterates | Hold → Hold | Get Alert |
| 12/03/2024 | Buy Now | 1.54% | Oppenheimer | Suraj Kalia59% | $125 → $125 | Maintains | Outperform | Get Alert |
| 12/03/2024 | Buy Now | — | Needham | Mike Matson57% | — | Reiterates | Hold → Hold | Get Alert |
| 11/22/2024 | Buy Now | -11.45% | Needham | Mike Matson57% | $109 → $109 | Downgrade | Buy → Hold | Get Alert |
| 11/20/2024 | Buy Now | -10.64% | Piper Sandler | Matt O'Brien53% | $180 → $110 | Maintains | Overweight | Get Alert |
| 11/20/2024 | Buy Now | -15.52% | Canaccord Genuity | William Plovanic60% | $109 → $104 | Maintains | Buy | Get Alert |
| 11/18/2024 | Buy Now | -2.52% | TD Cowen | Joshua Jennings56% | $175 → $120 | Maintains | Buy | Get Alert |
| 10/29/2024 | Buy Now | 46.22% | Piper Sandler | Matt O'Brien53% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 10/29/2024 | Buy Now | 1.54% | Oppenheimer | Suraj Kalia59% | $200 → $125 | Maintains | Outperform | Get Alert |
| 10/29/2024 | Buy Now | -5.77% | JP Morgan | Allen Gong46% | $173 → $116 | Maintains | Overweight | Get Alert |
| 10/29/2024 | Buy Now | -11.45% | Canaccord Genuity | Jason Mills81% | $169 → $109 | Maintains | Buy | Get Alert |
| 10/29/2024 | Buy Now | 21.85% | Baird | Joe Vruwink75% | $200 → $150 | Maintains | Outperform | Get Alert |
| 10/29/2024 | Buy Now | -11.45% | Needham | Mike Matson57% | $208 → $109 | Maintains | Buy | Get Alert |
| 10/07/2024 | Buy Now | 46.22% | Piper Sandler | Matt O'Brien53% | $180 → $180 | Maintains | Overweight | Get Alert |
| 09/24/2024 | Buy Now | 62.47% | Baird | Joe Vruwink75% | → $200 | Initiates | → Outperform | Get Alert |
| 08/23/2024 | Buy Now | 68.97% | Needham | Mike Matson57% | $208 → $208 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2024 | Buy Now | 68.97% | Needham | Mike Matson57% | → $208 | Initiates | → Buy | Get Alert |
| 08/02/2024 | Buy Now | 44.6% | Stephens & Co. | George Sellers39% | $151 → $178 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 46.22% | Piper Sandler | Matt O'Brien53% | $170 → $180 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 37.29% | Canaccord Genuity | Jason Mills81% | $117 → $169 | Maintains | Buy | Get Alert |
| 08/01/2024 | Buy Now | 62.47% | Oppenheimer | Suraj Kalia59% | $125 → $200 | Maintains | Outperform | Get Alert |
| 07/15/2024 | Buy Now | 17.79% | Morgan Stanley | Patrick Wood53% | $104 → $145 | Maintains | Equal-Weight | Get Alert |
| 07/15/2024 | Buy Now | 38.1% | Piper Sandler | Matt O'Brien53% | $120 → $170 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | -2.52% | Piper Sandler | Matt O'Brien53% | $120 → $120 | Maintains | Overweight | Get Alert |
| 06/07/2024 | Buy Now | 42.16% | TD Cowen | Joshua Jennings56% | $130 → $175 | Maintains | Buy | Get Alert |
| 06/04/2024 | Buy Now | 22.66% | Stephens & Co. | George Sellers39% | → $151 | Initiates | → Overweight | Get Alert |
| 05/01/2024 | Buy Now | -4.96% | Canaccord Genuity | Jason Mills81% | $102 → $117 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 5.61% | TD Cowen | Joshua Jennings56% | $100 → $130 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 3.17% | JP Morgan | Allen Gong46% | $105 → $127 | Maintains | Overweight | Get Alert |
| 05/01/2024 | Buy Now | -2.52% | Piper Sandler | Matt O'Brien53% | $95 → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 05/01/2024 | Buy Now | 1.54% | Oppenheimer | Suraj Kalia59% | $105 → $125 | Maintains | Outperform | Get Alert |
| 03/28/2024 | Buy Now | -22.83% | Piper Sandler | Matt O'Brien53% | → $95 | Initiates | → Overweight | Get Alert |
| 02/28/2024 | Buy Now | -22.83% | Morgan Stanley | Cecilia Furlong50% | $75 → $95 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | -14.7% | JP Morgan | Allen Gong46% | $87 → $105 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | -14.7% | Oppenheimer | Suraj Kalia59% | $92 → $105 | Maintains | Outperform | Get Alert |
| 12/04/2023 | Buy Now | -39.07% | Morgan Stanley | Cecilia Furlong50% | $54 → $75 | Maintains | Equal-Weight | Get Alert |
| 11/07/2023 | Buy Now | -43.14% | JP Morgan | Thomas Allen70% | $67 → $70 | Maintains | Overweight | Get Alert |
| 11/07/2023 | Buy Now | -56.13% | Morgan Stanley | Cecilia Furlong50% | $50 → $54 | Maintains | Equal-Weight | Get Alert |
| 10/13/2023 | Buy Now | -59.38% | Morgan Stanley | Cecilia Furlong50% | $81 → $50 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | -10.64% | TD Cowen | Joshua Jennings56% | $95 → $110 | Maintains | Outperform | Get Alert |
| 07/19/2023 | Buy Now | — | William Blair | — | — | Initiates | → Outperform | Get Alert |
| 05/18/2023 | Buy Now | -30.14% | Canaccord Genuity | William Plovanic60% | $91 → $86 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | -34.2% | Morgan Stanley | Cecilia Furlong50% | $74 → $81 | Maintains | Equal-Weight | Get Alert |
| 05/02/2023 | Buy Now | -26.89% | Oppenheimer | Suraj Kalia59% | $85 → $90 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | -39.07% | Cowen & Co. | Joshua Jennings56% | $70 → $75 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | -36.64% | Canaccord Genuity | William Plovanic60% | $68 → $78 | Maintains | Buy | Get Alert |
| 02/23/2023 | Buy Now | -34.2% | JP Morgan | Thomas Allen70% | $67 → $81 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -30.95% | Oppenheimer | Suraj Kalia59% | $55 → $85 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | -39.89% | Morgan Stanley | Cecilia Furlong50% | $63 → $74 | Maintains | Equal-Weight | Get Alert |
| 01/06/2023 | Buy Now | -48.82% | Morgan Stanley | Cecilia Furlong50% | $54 → $63 | Maintains | Equal-Weight | Get Alert |
| 11/04/2022 | Buy Now | -56.13% | Morgan Stanley | Cecilia Furlong50% | $45 → $54 | Maintains | Equal-Weight | Get Alert |
| 10/11/2022 | Buy Now | -63.44% | Morgan Stanley | Cecilia Furlong50% | $37 → $45 | Maintains | Equal-Weight | Get Alert |
| 08/03/2022 | Buy Now | -69.94% | Morgan Stanley | Cecilia Furlong50% | $34 → $37 | Maintains | Equal-Weight | Get Alert |
| 08/02/2022 | Buy Now | -63.44% | Oppenheimer | Suraj Kalia59% | $40 → $45 | Maintains | Outperform | Get Alert |
| 08/02/2022 | Buy Now | -61.01% | JP Morgan | Allen Gong46% | $26 → $48 | Upgrade | Neutral → Overweight | Get Alert |
| 07/26/2022 | Buy Now | -63.44% | Cowen & Co. | Joshua Jennings56% | $39 → $45 | Maintains | Outperform | Get Alert |
| 06/29/2022 | Buy Now | -72.38% | Morgan Stanley | Cecilia Furlong50% | $25 → $34 | Maintains | Equal-Weight | Get Alert |
| 06/28/2022 | Buy Now | -68.32% | Cowen & Co. | Joshua Jennings56% | $35 → $39 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for TransMedics Group (TMDX) stock?
The latest price target for TransMedics Group (NASDAQ:TMDX) was reported by Oppenheimer on May 9, 2025. The analyst firm set a price target for $130.00 expecting TMDX to rise to within 12 months (a possible 5.61% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TransMedics Group (TMDX)?
The latest analyst rating for TransMedics Group (NASDAQ:TMDX) was provided by Oppenheimer, and TransMedics Group maintained their outperform rating.
When was the last upgrade for TransMedics Group (TMDX)?
The last upgrade for TransMedics Group Inc happened on August 2, 2022 when JP Morgan raised their price target to $48. JP Morgan previously had a neutral for TransMedics Group Inc.
When was the last downgrade for TransMedics Group (TMDX)?
The last downgrade for TransMedics Group Inc happened on December 17, 2024 when JP Morgan changed their price target from $116 to $75 for TransMedics Group Inc.
When is the next analyst rating going to be posted or updated for TransMedics Group (TMDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransMedics Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransMedics Group was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.
Is the Analyst Rating TransMedics Group (TMDX) correct?
While ratings are subjective and will change, the latest TransMedics Group (TMDX) rating was a maintained with a price target of $125.00 to $130.00. The current price TransMedics Group (TMDX) is trading at is $123.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
